Sotatercept Cuts Death and Hospitalization by 76% in High-Risk Lung Hypertension
A landmark phase 3 trial stopped early for efficacy shows sotatercept dramatically reduces composite mortality and hospitalization in advanced PAH patients.
Summary
The ZENITH trial tested sotatercept — an activin receptor fusion protein — added onto maximum background therapy in 172 adults with high-risk pulmonary arterial hypertension (WHO class III/IV). The trial was halted early due to striking efficacy: only 17.4% of sotatercept patients experienced a primary endpoint event (death, lung transplant, or worsening-related hospitalization) versus 54.7% on placebo — a 76% relative risk reduction. Deaths occurred in 8.1% vs 15.1%, and hospitalizations for worsening PAH in 9.3% vs 50%. Side effects included epistaxis and telangiectasia. These results suggest sotatercept offers a major therapeutic advance even for the most critically ill PAH patients already on optimized conventional treatment.
Detailed Summary
Pulmonary arterial hypertension (PAH) remains a life-threatening disease characterized by progressive vascular remodeling and right heart failure. Even with modern combination therapy, high-risk patients face a 1-year mortality rate exceeding 20%, highlighting an urgent unmet need for treatments that address the underlying vascular biology rather than just vasodilation.
The ZENITH trial enrolled 172 patients with WHO functional class III or IV PAH and a high estimated 1-year mortality risk (REVEAL Lite 2 score ≥9), all already receiving the maximum tolerated background therapy. Participants were randomized to subcutaneous sotatercept (escalated from 0.3 to 0.7 mg/kg every 3 weeks) or placebo. Sotatercept works by trapping ligands in the TGF-β superfamily, thereby counteracting the pro-proliferative signaling thought to drive pulmonary vascular remodeling.
The trial was stopped early at a prespecified interim analysis due to overwhelming efficacy. The composite primary endpoint — death, lung transplantation, or hospitalization ≥24 hours for worsening PAH — occurred in just 17.4% of sotatercept recipients versus 54.7% of placebo recipients (HR 0.24; 95% CI 0.13–0.43; P<0.001). All three components trended in favor of sotatercept: mortality 8.1% vs 15.1%, transplantation 1.2% vs 7.0%, and worsening hospitalizations 9.3% vs 50.0%.
These results extend sotatercept's proven benefits from moderate-severity PAH (STELLAR trial) into the highest-risk patient population. The magnitude of benefit — a 76% relative risk reduction — is extraordinary for any cardiovascular intervention in a critically ill cohort already on optimized therapy.
Caveats include the relatively small sample size (trial stopped early), short follow-up duration due to early termination, and industry funding by Merck, which manufactured sotatercept. Long-term safety and durability of benefit require further study.
Key Findings
- Sotatercept reduced the composite primary endpoint by 76% vs placebo (17.4% vs 54.7%; HR 0.24).
- All-cause mortality was nearly halved: 8.1% sotatercept vs 15.1% placebo.
- PAH-related hospitalizations dropped dramatically from 50.0% to 9.3% with sotatercept.
- The trial was stopped early at interim analysis due to overwhelming efficacy.
- Most common adverse events were epistaxis and telangiectasia, consistent with prior sotatercept trials.
Methodology
Phase 3 randomized, double-blind, placebo-controlled trial (ZENITH; NCT04896008) enrolling 172 high-risk PAH patients (WHO class III/IV; REVEAL Lite 2 ≥9) across international sites. Patients received subcutaneous sotatercept or placebo every 3 weeks added to maximum tolerated background therapy. Primary endpoint was a time-to-first-event composite of death, lung transplantation, or ≥24-hour hospitalization for worsening PAH; trial was stopped early at a prespecified interim analysis.
Study Limitations
The trial was stopped early, which can overestimate treatment effects and limits assessment of long-term outcomes. The sample size of 172 patients is modest, reducing precision of subgroup analyses. Industry funding by Merck introduces potential conflict of interest, and longer follow-up is needed to confirm durability of benefit and characterize rare adverse events.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.